PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26622694-1 2015 The aim of the present study was to investigate the mutational status of exons 1 and 2 of the p16 gene in the exhaled breath condensate (EBC) of patients with non-small-cell lung cancer (NSCLC) and determine the feasibility and clinical significance of applying EBC in the diagnosis of NSCLC. NSC638702 137-140 cyclin dependent kinase inhibitor 2A Homo sapiens 94-97 26622694-1 2015 The aim of the present study was to investigate the mutational status of exons 1 and 2 of the p16 gene in the exhaled breath condensate (EBC) of patients with non-small-cell lung cancer (NSCLC) and determine the feasibility and clinical significance of applying EBC in the diagnosis of NSCLC. NSC638702 262-265 cyclin dependent kinase inhibitor 2A Homo sapiens 94-97 24268095-4 2014 RESULTS: The positive rate of aberrant promoter methylation of P16 was 26 of 30 (86.66%) in tumor tissues, 15 of 30 (50%) in blood plasma, and 12 of 30 (40%) in EBC, we have not observed the positive methylation of P16 in the adjacent normal lung tissues, or in EBC or blood plasma from the healthy control group. NSC638702 161-164 cyclin dependent kinase inhibitor 2A Homo sapiens 63-66 24268095-4 2014 RESULTS: The positive rate of aberrant promoter methylation of P16 was 26 of 30 (86.66%) in tumor tissues, 15 of 30 (50%) in blood plasma, and 12 of 30 (40%) in EBC, we have not observed the positive methylation of P16 in the adjacent normal lung tissues, or in EBC or blood plasma from the healthy control group. NSC638702 262-265 cyclin dependent kinase inhibitor 2A Homo sapiens 63-66 24268095-5 2014 CONCLUSION: We found that detected promoter methylation of P16 in EBC was feasibility, it should be an useful biomarker for diagnosis of NSCLC, it have potential prospect that detected the gene molecular in EBC because of noninvasive, specificity, convenient and repeatable. NSC638702 66-69 cyclin dependent kinase inhibitor 2A Homo sapiens 59-62 24268095-5 2014 CONCLUSION: We found that detected promoter methylation of P16 in EBC was feasibility, it should be an useful biomarker for diagnosis of NSCLC, it have potential prospect that detected the gene molecular in EBC because of noninvasive, specificity, convenient and repeatable. NSC638702 207-210 cyclin dependent kinase inhibitor 2A Homo sapiens 59-62